- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Review, Journal: The Role of Insulin-like Growth Factor-1 and Its Receptor in the Eye: A Review and Implications for IGF-1R Inhibition. (Pubmed Central) - Jan 5, 2023
Carefully designed studies and clinical assessments of patients undergoing treatment with anti-IGF-1R may identify ocular side effects and foster consideration of the role of anti-IGF-1R in ocular therapeutics. Given the increasing use of anti-IGF-1R antibodies, understanding their ocular effects, side effects, and potential systemic implications for use in disease is critical.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Review, Journal: Thyroid Eye Disease. (Pubmed Central) - Dec 24, 2022
Diagnosis and evaluation include careful physical examination, targeted laboratory work up, appropriate imaging studies, and tailored treatment regimens. Special consideration may apply to certain populations, such as pediatric and pregnant patients.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) (clinicaltrials.gov) - Dec 21, 2022
P1, N=3, Terminated,
Special consideration may apply to certain populations, such as pediatric and pregnant patients. N=25 --> 3 | Trial completion date: Sep 2023 --> Dec 2022 | Recruiting --> Terminated | Trial primary completion date: Apr 2023 --> Nov 2022; Poor enrollment
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Review, Journal: Teprotumumab: A Review in Thyroid Eye Disease. (Pubmed Central) - Nov 24, 2022
Teprotumumab is the first approved treatment for TED and is effective at reducing symptoms which are often unamenable to historical pharmacological interventions. While further data are required, current evidence suggests teprotumumab represents an important advance in the treatment of TED.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche, Actemra IV (tocilizumab) / Roche, JW Pharma
Journal: Graves' orbitopathy post-SARS-CoV-2 vaccines: report on six patients. (Pubmed Central) - Nov 17, 2022
Clinicians need to be aware of the risk of new-onset or recurrent GO in predisposed patients with autoimmune thyroid diseases after COVID-19 vaccination. This study should not raise any concerns regarding SARS-CoV-2 vaccination since the risk of COVID-19 undoubtedly outweighs the incidence of uncommon GO after SARS-CoV-2 vaccination.
- |||||||||| Journal: Future Projections in Thyroid Eye Disease. (Pubmed Central) - Nov 15, 2022
New, albeit incomplete, understanding of the molecular mechanisms of TED has led to new promising therapies and offered improved outcomes in TED patients. Their full role and their relationship to classical immune suppression should be clarified over the next few years.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Clinical, Review, Journal: Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease. (Pubmed Central) - Nov 15, 2022
Teprotumumab has demonstrated superior efficacy to conventional treatments and has transformed our therapeutic and surgical algorithms. Clinical guidelines and additional studies are needed to further guide and refine therapy.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche, Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease. (Pubmed Central) - Nov 15, 2022
These include teprotumumab, rituximab, and tocilizumab. Restoration of immune tolerance could ultimately become the most effective and safe medical management for TED.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Enrollment closed, Trial completion date, Trial primary completion date: A Study Evaluating TEPEZZA (clinicaltrials.gov) - Nov 8, 2022
P4, N=62, Active, not recruiting,
Restoration of immune tolerance could ultimately become the most effective and safe medical management for TED. Recruiting --> Active, not recruiting | Trial completion date: Apr 2023 --> Oct 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Teprotumumab as a novel treatment for pretibial myxedema. (Pubmed Central) - Nov 5, 2022
Recruiting --> Active, not recruiting | Trial completion date: Apr 2023 --> Oct 2023 | Trial primary completion date: Sep 2022 --> Mar 2023 No abstract available
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
TEPROTUMUMAB‐RELATED HYPERGLYCEMIA () - Oct 26, 2022 - Abstract #ATA2022ATA_361;
Thirty percent of our patients experienced a ≥0.5% increase in HgbA1c, seen mostly in those with diabetes. These findings support the development of guidelines for screening and management of hyperglycemia surrounding teprotumumab therapy.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Role of teprotumumab in the treatment of active moderate-to-severe Graves' orbitopathy. (Pubmed Central) - Oct 18, 2022
In the large majority of cases GO is mild, self-limiting and non-progressive, requiring only local measures (artificial tears, ophthalmic gels) and control of risk factors. Very rarely, GO is sight-threatening, due to compressive dysthyroid optic neuropathy (DON) and/or exophthalmos-related corneal breakdown, requiring prompt treatment with very high doses of intravenous glucocorticoids (ivGCs), local treatments, and/or orbital decompression surgery.
- |||||||||| Review, Journal: Current concepts regarding Graves' orbitopathy. (Pubmed Central) - Oct 15, 2022
The aim of this review is to provide an updated overview of current concepts regarding epidemiology, pathogenesis, assessment, and treatment of GO, and to present emerging targeted therapies and therapeutic perspectives. Original articles, clinical trials, systematic reviews, and meta-analyses from 1980 to 2021 were searched using the following terms: Graves' disease, Graves' orbitopathy, thyroid eye disease, glucocorticoids, orbital radiotherapy, rituximab, cyclosporine, azathioprine, teprotumumab, TSH-receptor antibody, smoking, hyperthyroidism, hypothyroidism, thyroidectomy, radioactive iodine, and antithyroid drugs.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Literature Commentary. (Pubmed Central) - Oct 5, 2022
Epub ahead of print. PMID: 35364222.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Teprotumumab divergently alters fibrocyte gene expression: Implications for thyroid-associated ophthalmopathy. (Pubmed Central) - Sep 30, 2022
The current results suggest that the drug may act on cytokine expression and HA production systemically and locally, within the TAO orbit. These findings extend our insights into the mechanisms through which IGF-IR inhibition might elicit clinical responses in TAO, including a potential role of Slit2 in attenuating inflammation and tissue remodeling.
- |||||||||| Reevaluating Clinical Outcomes of Patients on Combination Biologics (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2143;
Further inquiry is required to determine if certain combinations biologics have a safer risk profile than others. Many biologics were not included in study due lack of unique J-code.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche, Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)] (Pubmed Central) - Sep 7, 2022
EUGOGO guidelines recommend that in cases of no clinical response after 6 weeks of first-line treatment with i.v. methylprednisolone and mycophenolate, after 3-4 weeks, a second course of i.v. methylprednisolone monotherapy should be started with a higher cumulative dose of 7.5 g. Other second-line treatment options are orbital radiotherapy with or without oral or i.v. systemic glucocorticosteroid therapy, cyclosporine, or azathioprine in combination with p.o. glucocorticosteroid, methotrexate monotherapy, and a group of biologic drugs rituximab, tocilizumab, teprotumumab). Keeping in mind that TO is a sight-threatening disease, we expect, through the treatment applied, to maintain full visual acuity, pain relief, single vision in the useful part of the visual field, and a positive cosmetic effect.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Insulin-Like Growth Factor I Receptor Inhibitor-Induced Inflammatory Bowel Disease (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_2062;
This case highlights a potentially detrimental side effect and appropriate discussions with patients should be held prior to this medications usage. Ideally the gastroenterologist should be kept abreast of the decision to initiate such therapy to allow for careful monitoring.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Teprotumumab (Tepezza) for Thyroid Eye Disease. (Pubmed Central) - Aug 30, 2022
Teprotumumab is currently the only Federal Drug Administration approved therapy for the treatment of TED. Significant improvements in proptosis, diplopia and quality of life are noted following its 24-week course of therapy.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Teprotumumab for chronic thyroid eye disease. (Pubmed Central) - Aug 24, 2022
We report clinically and statistically significant proptosis reduction in nine patients with chronic, low CAS TED treated with teprotumumab. Teprotumumab may be an effective treatment option for these patients.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Retrospective data, Review, Journal, HEOR: Comparative effectiveness of different treatment modalities for active, moderate-to-severe Graves' orbitopathy: a systematic review and network meta-analysis. (Pubmed Central) - Aug 13, 2022
With regard to different dosages of IVGCs, the cumulative dose of 4.5-5 g of IVGCs seems to be the most appropriate schedule in terms of efficacy and safety outcomes. Due to the limited number of patients treated with teprotumumab and the lack of comparison with other effective therapeutics, teprotumumab might not become the standard first-line therapy for active, moderate-to-severe GO.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
LL02 - Does My Patient Need Tepezza? (LEARNING LOUNGE 2) - Aug 8, 2022 - Abstract #AAO2022AAO_1298;
New topics begin every 30 minutes. Float among the discussions and interact with colleagues.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Teprotumumab for the treatment of chronic thyroid eye disease. (Pubmed Central) - Jul 28, 2022
Float among the discussions and interact with colleagues. Teprotumumab significantly reduces proptosis, inflammation, diplopia, strabismus and orbital soft tissue volume in patients with chronic TED.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Hearing Dysfunction After Treatment with Teprotumumab for Thyroid Eye Disease. (Pubmed Central) - Jul 28, 2022
Until risk factors for hearing loss are better understood, we recommend baseline audiometry with PET testing and repeat testing if new otologic symptoms develop. Screening, monitoring, and prevention guidelines are needed.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Treating Thyroid Associated Ophthalmopathy in Pediatric Patients. (Pubmed Central) - Jul 23, 2022
Considering the nature of the target, Teprotumumab should not be used empirically in children. More efforts would be made for the further development of teprotumumab for pediatric use.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Reversal of Graves' Disease Associated Facial Volume Expansion and Eyelid Changes Following Teprotumumab Therapy () - Jul 16, 2022 - Abstract #ENDO2022ENDO_2775;
Thyroid eye disease has a significant negative impact on the quality of life of patients, this is connected to facial appearance. Given the importance of facial appearance on the quality of life of patients with TED, we believe the term thyroid face disease as opposed to thyroid eye disease may be more informative for patients.Awards: Endocrine Society Outstanding Abstract Award,
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Teprotumumab Reduces Orbital Fat And Muscle Volume In Patients With Thyroid Eye Disease () - Jul 16, 2022 - Abstract #ENDO2022ENDO_2658;
Science Topic(s) for Thryoid: Non-neoplastic Thyroid Disorders Learning Objective 1: Teprotumumab reduces proptosis in patients with thyroid eye disease Learning Objective 2: Teprotumumab reduces Thyroid eye disease related orbital muscle expansion Topical area for Clinical Case Reports: Thyroid
|
